In this study, we evaluated the safety, tolerability, preliminary efficacy, and DNA methylome dynamics after treatment with the methyl donor, l-methylfolate, combined with temozolomide and bevacizumab in recurrent IDH wild-type high-grade gliomas. The gene discussed is IDH2; the disease is glioma.